---
document_datetime: 2023-09-21 21:22:56
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/scientific-discussion/glubrava-epar-scientific-discussion_en.pdf
document_name: glubrava-epar-scientific-discussion_en.pdf
version: success
processing_time: 1.3568507
conversion_datetime: 2025-12-22 16:14:40.950227
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1. Introduction

This application has been submitted as an informed consent application in accordance with Article 10c of Directive 2001/83/EC as amended.

Therefore, consent from the MAH of the Competact application, which had been submitted as a full application under Art 8(3) of Directive 2001/83/EC as amended, has been given allowing access to Module  2  to  Module  5  of  the  initial  dossier  of  this  authorised  product  and  any  subsequent  postmarketing procedures submitted, assessed and approved.

Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. This formulation combines two antihyperglycaemic agents with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class. Thiazolidinediones  act  primarily  by  reducing  insulin  resistance  and  biguanides  act  primarily  by decreasing endogenous hepatic glucose production. Quality,  safety  and  efficacy  of  Pioglitazone/Metformin  hydrochloride  Takeda  15  mg/850  mg  filmcoated tablets are identical to the up to date quality, safety and efficacy profile of Competact. The application for Pioglitazone/Metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets consists only of Module 1 information. The  approved  indication  is:  treatment  of  type  2  diabetes  mellitus  patients,  particularly  overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. 2. Quality aspects Since this application is an informed consent of the Competact application, the quality data in support of the Pioglitazone/Metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets application are identical  to  the  up-to-date  quality  data  of  the  Competact  dossier  which  have  been  assessed  and approved (including all post-marketing procedures). 3. Non-clinical aspects Since this application is an informed consent of the Competact application, the non-clinical data in support  of  the  Pioglitazone  /  metformin  hydrochloride  Takeda  15  mg/850  mg  film-coated  tablets application are identical to the up-to-date non-clinical data of the Competact dossier, which have been assessed and approved (including all post-marketing procedures). Medicinal Product no longer authorised

## 4. Clinical aspects

Since this application is an informed consent of the Competact application, the clinical data in support of the Pioglitazone / metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets application are identical to the up-to-date clinical data of the Competact dossier, which have been assessed and approved (including all post-marketing procedures).

## SCIENTIFIC DISCUSSION

<div style=\"page-break-after: always\"></div>

## Â· User Consultation

Consultation  with  target  patient  groups  has  not  been  undertaken  for  Pioglitazone  /  metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets. However as part of a follow up measure for the reference product Competact, readability testing was performed and reviewed by the CHMP. The updates to the Competact Package Leaflet in view of the assessment of this follow up measure have also been taken into account in the Pioglitazone/Metformin hydrochloride Takeda 15 mg/850 mg filmcoated tablets package leaflet.

## 5. Pharmacovigilance

<!-- image -->

| Safety issue                              | Proposed pharmacovigilance activities                                                                                                                                                                                                                           | Proposed risk minimisation activities                                                                                                                                                                                                       |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hepatic dysfunction                       | 1. Routine pharmacovigilance including review in PSURs 2. Annual review and report on Hepato-biliary events. 3. Results from completed hepatic safety study in pioglitazone 4. Trend analysis on frequency of reporting. no                                     | Contraindication for use in hepatic impairment in section 4.3 of the SPC. Precautions and recommendations for assessing ALT levels in section 4.4 of the SPC. Elevated hepatic function tests and hepatocellular dysfunction in section 4.8 |
| Heart failure                             | 1. Routine pharmacovigilance including review in PSURs 2. Analysis from ongoing clinical trials 3. Final analysis of PROactive long-term trial. Product                                                                                                         | Contraindication in section 4.3 of the SPC Precautions and recommendations in section 4.4 of the SPC.                                                                                                                                       |
| Weight gain / peripheral oedema Medicinal | 1. Routine pharmacovigilance including review in PSURs 2. Results from PROactive study 3. Analysis from ongoing clinical trials 4. Pioglitazone clinical trial to investigate mechanisms 5. Review of ADR reports to assess compliance with SPC recommendations | Precautions and recommendations in section 4.4 of the SPC.                                                                                                                                                                                  |
| Neoplasia                                 | 1. Routine pharmacovigilance including review in PSURs 2. Analysis from ongoing clinical trials 3. Final study report from PROactive study and long term follow up. 4. Analyses from KPNC cohort study                                                          | Statement of finding of bladder hyperplasia / neoplasia in rats in section 5.3 of the SPC.                                                                                                                                                  |

Detailed description of the Pharmacovigilance system The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements. Risk Management Plan The MAA submitted a risk management plan, which included a risk minimisation plan. Table: Summary of the risk management plan Medicinal Product no longer authorised

<div style=\"page-break-after: always\"></div>

|                | 5. Non-clinical study in male rats                                                                                                |                                                                                                                                                                                      |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Macular oedema | 1. Routine pharmacovigilance including review in PSURs. 2. Pioglitazone clinical trial to investigate mechanisms                  | RMP, risk minimisation for macular oedema: Warning in Section 4.4 of the SPC for macular oedema and decreased visual acuity; mentioning of macular oedema as ADR in Section 4.8 SPC. |
| Bone fracture  | 1. Routine pharmacovigilance including review in PSURs. 2. Expert consultation to evaluate feasibility of further investigations. | Section 4.4 and 4.8 of the SmPC and the Package Leaflet updated to reflect finding.                                                                                                  |

<!-- image -->

The CHMP, having considered the data submitted in the application, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information. 6. Overall conclusions, risk/benefit assessment and recommendation Since this application is an informed consent of the Competact application, the CHMP considered that the risk-benefit balance of Pioglitazone / metformin hydrochloride Takeda 15 mg/850 mg film-coated tablets was favourable and therefore recommended the granting of the marketing authorisation for the following indication: Treatment  of  type  2  diabetes  mellitus  patients,  particularly  overweight  patients,  who  are  unable  to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone. Medicinal Product no longer authorised